Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
CERo Therapeutics Holdings has filed a Prospectus Supplement No. 3 (424B3) updating their May 23, 2025 prospectus for 2,100,000 shares of common stock. The company's stock (NASDAQ: CERO) last traded at $9.56 per share, while its warrants (CEROW) traded at $0.0264.
The key development reported is that the FDA has granted Orphan Drug Designation to the company's lead drug candidate CER-1236 for treating acute myeloid leukemia, as announced on June 17, 2025.
As an emerging growth company, CERo Therapeutics trades on the Nasdaq Capital Market. The filing includes important risk disclosures for investors, and the company has not elected to use the extended transition period for complying with new financial accounting standards.
- Common stock par value: $0.0001 per share
- Warrants: Each exercisable for 1/2000th of a common share
- Principal office: South San Francisco, CA
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
FAQ
How many CERO THERAPEUTICS HOLDINGS (CERO) SEC filings are available on StockTitan?
StockTitan tracks 74 SEC filings for CERO THERAPEUTICS HOLDINGS (CERO), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.
When was the most recent SEC filing for CERO THERAPEUTICS HOLDINGS (CERO)?
The most recent SEC filing for CERO THERAPEUTICS HOLDINGS (CERO) was filed on July 8, 2025.